Over the years, Ally Bridge Group has invested through the following strategies: 1) venture; 2) private equity, including buyout and growth capital; 3) public equity.

  1. Venture – investing in innovative life science companies at early to developmental stages primarily in the US, both private and public, focused on innovative drugs, medical devices and diagnostics.
  2. Buyout and large growth capital – investing in cashflow-generating life science companies in China, Europe and the US. We leverage our unique strengths in capital markets, M&A and global cross-border investing, deal-making, execution, and enabling of cross-border business development & partnerships.
  3. Public equity – employing fundamental and bottom-up research-driven, with a proactive value-add approach to investing in public equities from Asia to the US.

Today and going forward, Ally Bridge Group primarily focuses on leading high-impact investments in later-stage cutting-edge life science innovations in the U.S. across the medtech, tools and diagnostics, biopharmaceutics and, increasingly, digital health/telemedicine sectors – in both the private and public markets in an integrated fashion.